Back to User profile » Dr Yingqun Zhou

Papers published by Dr Yingqun Zhou:


Identification and Characterization of a Novel Nanobody Against Human CTGF to Reveal Its Antifibrotic Effect in an in vitro Model of Liver Fibrosis

Liu R, Zhu M, Chen J, Gai J, Huang J, Zhou Y, Wan Y, Tu C

International Journal of Nanomedicine 2023, 18:5407-5422

Published Date: 21 September 2023

Beraprost sodium preconditioning prevents inflammation, apoptosis, and autophagy during hepatic ischemia-reperfusion injury in mice via the P38 and JNK pathways

Deng J, Feng J, Liu T, Lu X, Wang W, Liu N, Lv Y, Liu Q, Guo C, Zhou Y

Drug Design, Development and Therapy 2018, 12:4067-4082

Published Date: 29 November 2018

Epigallocatechin-3-gallate attenuates apoptosis and autophagy in concanavalin A-induced hepatitis by inhibiting BNIP3

Li S, Xia Y, Chen K, Li J, Liu T, Wang F, Lu J, Zhou Y, Guo C

Drug Design, Development and Therapy 2016, 10:631-647

Published Date: 15 February 2016

Protective effect of fucoidan from Fucus vesiculosus on liver fibrosis via the TGF-β1/Smad pathway-mediated inhibition of extracellular matrix and autophagy

Li J, Chen K, Li S, Feng J, Liu T, Wang F, Zhang R, Xu S, Zhou Y, Zhou S, Xia Y, Lu J, Zhou Y, Guo C

Drug Design, Development and Therapy 2016, 10:619-630

Published Date: 12 February 2016

Inhibitive effects of 15-deoxy-Δ12,14-prostaglandin J2 on hepatoma-cell proliferation through reactive oxygen species-mediated apoptosis

Chen K, Dai W, Wang F, Xia Y, Li J, Li S, Liu T, Zhang R, Wang J, Lu W, Zhou Y, Yin Q, Zheng Y, Abudumijiti H, Chen R, Lu J, Zhou Y, Guo C

OncoTargets and Therapy 2015, 8:3585-3593

Published Date: 1 December 2015

Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis [Erratum]

Yin Q, Li J, Xia Y, Zhang R, Wang J, Lu W, Zhou Y, Zheng Y, Abudumijiti H, Chen R, Chen K, Li S, Liu T, Wang F, Lu J, Zhou Y, Guo C

Drug Design, Development and Therapy 2015, 9:5947-5948

Published Date: 9 November 2015

Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis

Yin Q, Li J, Xia Y, Zhang R, Wang J, Lu W, Zhou Y, Zheng Y, Abudumijiti H, Chen R, Chen K, Li S, Liu T, Wang F, Lu J, Zhou Y, Guo C

Drug Design, Development and Therapy 2015, 9:5407-5419

Published Date: 30 September 2015

Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis

Zhang Y, Li S, He L, Wang F, Chen K, Li J, Liu T, Zheng Y, Wang J, Lu W, Zhou Y, Yin Q, Xia Y, Zhou Y, Lu J, Guo C

Drug Design, Development and Therapy 2015, 9:2757-2766

Published Date: 25 May 2015

Combination therapy of ursodeoxycholic acid and budesonide for PBC–AIH overlap syndrome: a meta-analysis

Zhang H, Yang J, Zhu R, Zheng Y, Zhou Y, Dai W, Wang F, Chen K, Li J, Wang C, Li S, Liu T, Abudumijiti H, Zhou Z, Wang J, Lu W, Wang J, Xia Y, Zhou Y, Lu J, Guo C

Drug Design, Development and Therapy 2015, 9:567-574

Published Date: 17 January 2015

Hydrogen sulfide, a potential novel drug, attenuates concanavalin A-induced hepatitis

Cheng P, Chen K, Xia Y, Dai WQ, Wang F, Shen M, Wang C, Yang J, Zhu R, Zhang H, Li JJ, Zheng Y, Wang J, Zhang Y, Lu J, Zhou YQ, Guo CY

Drug Design, Development and Therapy 2014, 8:1277-1286

Published Date: 9 September 2014